Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 2.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 60,507 shares of the biopharmaceutical company’s stock after buying an additional 1,420 shares during the quarter. Victory Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $13,699,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ALNY. Nuveen Asset Management LLC lifted its holdings in Alnylam Pharmaceuticals by 5,486.1% during the 3rd quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock worth $3,321,309,000 after buying an additional 16,296,223 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $103,909,000. Eaton Vance Management raised its holdings in shares of Alnylam Pharmaceuticals by 606.7% in the 1st quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock valued at $50,005,000 after purchasing an additional 262,893 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $43,377,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Alnylam Pharmaceuticals by 55.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 535,599 shares of the biopharmaceutical company’s stock valued at $107,206,000 after purchasing an additional 191,310 shares in the last quarter.

Alnylam Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:ALNY opened at $191.83 on Wednesday. The company has a market cap of $23.89 billion, a price-to-earnings ratio of -22.07 and a beta of 0.48. The firm’s 50-day simple moving average is $199.27 and its 200-day simple moving average is $212.24. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $120.43 and a fifty-two week high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.57. The business had revenue of $319.29 million for the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative net margin of 93.13% and a negative return on equity of 1,287.80%. The business’s quarterly revenue was up 49.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.00) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.59 EPS for the current year.

Insider Activity

In other news, CMO Pushkal Garg sold 18,072 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $200.00, for a total value of $3,614,400.00. Following the sale, the chief marketing officer now owns 4,345 shares of the company’s stock, valued at $869,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Jeffrey V. Poulton sold 977 shares of the firm’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $190,114.43. Following the completion of the sale, the chief financial officer now owns 11,706 shares in the company, valued at $2,277,870.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 18,072 shares of the firm’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the completion of the sale, the chief marketing officer now owns 4,345 shares of the company’s stock, valued at approximately $869,000. The disclosure for this sale can be found here. Insiders have sold a total of 35,871 shares of company stock valued at $7,131,842 over the last quarter. Corporate insiders own 1.40% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of analyst reports. BMO Capital Markets upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $200.00 to $250.00 in a report on Friday, May 5th. Canaccord Genuity Group reduced their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a report on Friday, February 24th. StockNews.com assumed coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, May 18th. They issued a “buy” rating on the stock. Oppenheimer cut their price target on shares of Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th. Finally, Citigroup cut their price target on shares of Alnylam Pharmaceuticals from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $247.20.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.